Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19902539 | 0.96 | PARP1 (0.48) | PARP1GAAPTK2BPPARGRXFP1 | |
| SCHEMBL1251951 | 0.81 | POLB (0.51) | PARP1 | |
| SCHEMBL18237877 | 0.79 | MEN1 (0.36) | PARP1GAAPTK2BSMN1; SMN2 | |
| SCHEMBL18238523 | 0.79 | MEN1 (0.36) | PARP1 | |
| SCHEMBL11914651 | 0.78 | HCAR2 (0.46) | GAAPTK2BRXFP1SMN1; SMN2 | |
| SCHEMBL19131102 | 0.78 | PARP1 (0.35) | PARP1 | |
| SCHEMBL19131869 | 0.78 | PARP1 (0.46) | PARP1 | |
| SCHEMBL18237565 | 0.78 | PARP1 (0.40) | PARP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18237564 | 0.78 | PARP1 (0.35) | PARP1GAAPTK2BPPARGRXFP1 | |
| SCHEMBL18237613 | 0.78 | PARP1 (0.40) | PARP1GAAPTK2BPPARGRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730858-B2 | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3481816-B1 | LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20190300510-A1 | LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-03 | — | — | US | disclosed |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300510-A1 | LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS | MYLK, ROCK1, ROCK2 | PARP1 1082/4885GAA 3153/4885PTK2B 1398/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | PARP1 2195/4885GAA 36/4885PTK2B 2067/4885 |
| US-10730858-B2 | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors | MYLK, ROCK1, MYLK2 | PARP1 914/4885GAA 3385/4885PTK2B 1237/4885 |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | PARP1 1915/4885GAA 4260/4885PTK2B 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.